New hope for kids with dangerous transplant complication
NCT ID NCT04557735
Summary
This study tested a medication called ravulizumab in children who developed a dangerous blood clotting disorder (TMA) after a stem cell transplant. The goal was to see if adding this drug to standard care could help control the disorder by improving blood counts and kidney function. Forty-one children under 18 received the drug through an IV for 26 weeks, followed by 26 weeks of observation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Tucson, Arizona, 85724, United States
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Portland, Oregon, 97239, United States
-
Research Site
Dallas, Texas, 75235, United States
-
Research Site
Salt Lake City, Utah, 84108, United States
-
Research Site
Madison, Wisconsin, 53792, United States
-
Research Site
Haifa, 91096, Israel
-
Research Site
Jerusalem, 91120, Israel
-
Research Site
Petah Tikva, 4920235, Israel
-
Research Site
Ramat Gan, 5265601, Israel
-
Research Site
Roma, 00165, Italy
-
Research Site
Fukushima, 960-1295, Japan
-
Research Site
Kobe, 650-0047, Japan
-
Research Site
Nagoya, 466-8560, Japan
-
Research Site
Osaka, 534-0021, Japan
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 5505, South Korea
-
Research Site
Barcelona, 08041, Spain
-
Research Site
Esplugues de Llobregat, 8950, Spain
-
Research Site
Madrid, 28046, Spain
-
Research Site
Salamanca, 37007, Spain
-
Research Site
Birmingham, B4 6NH, United Kingdom
-
Research Site
Bristol, BS2 8BJ, United Kingdom
-
Research Site
Newcastle upon Tyne, NE1 4LP, United Kingdom
Conditions
Explore the condition pages connected to this study.